Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 2
2022 4
2023 5
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Advances in Radioligand Theranostics in Oncology.
Lawal IO, Abubakar SO, Ndlovu H, Mokoala KMG, More SS, Sathekge MM. Lawal IO, et al. Among authors: ndlovu h. Mol Diagn Ther. 2024 May;28(3):265-289. doi: 10.1007/s40291-024-00702-4. Epub 2024 Mar 31. Mol Diagn Ther. 2024. PMID: 38555542 Review.
Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study.
Sathekge MM, Lawal IO, Bal C, Bruchertseifer F, Ballal S, Cardaci G, Davis C, Eiber M, Hekimsoy T, Knoesen O, Kratochwil C, Lenzo NP, Mahapane J, Maserumule LC, Mdlophane AH, Mokoala KMG, Ndlovu H, Pant V, Rathke H, Reed J, Sen IB, Singh A, Sood A, Tauber R, Thakral P, Yadav MP, Morgenstern A. Sathekge MM, et al. Among authors: ndlovu h. Lancet Oncol. 2024 Feb;25(2):175-183. doi: 10.1016/S1470-2045(23)00638-1. Epub 2024 Jan 11. Lancet Oncol. 2024. PMID: 38218192
COVID-19 Is a Multi-Organ Aggressor: Epigenetic and Clinical Marks.
Kgatle MM, Lawal IO, Mashabela G, Boshomane TMG, Koatale PC, Mahasha PW, Ndlovu H, Vorster M, Rodrigues HG, Zeevaart JR, Gordon S, Moura-Alves P, Sathekge MM. Kgatle MM, et al. Among authors: ndlovu h. Front Immunol. 2021 Oct 8;12:752380. doi: 10.3389/fimmu.2021.752380. eCollection 2021. Front Immunol. 2021. PMID: 34691068 Free PMC article. Review.
Prognostic Value of PSMA PET/CT in Prostate Cancer.
Lawal IO, Ndlovu H, Kgatle M, Mokoala KMG, Sathekge MM. Lawal IO, et al. Among authors: ndlovu h. Semin Nucl Med. 2024 Jan;54(1):46-59. doi: 10.1053/j.semnuclmed.2023.07.003. Epub 2023 Jul 22. Semin Nucl Med. 2024. PMID: 37482489 Review.
The SARS-COV-2 Seroprevalence among Oncology Patients.
Kgatle M, Das R, Lawal I, Boshomane T, Mokoala K, Gaspar C, Mbokazi L, Nkambule N, Gow V, Ndlovu H, Mzizi Y, Chalwe J, Diphofa J, Mokobodi D, Gxekwa N, Zongo L, Maphosa T, Vorster M, Bassa S, Venkatesan A, Khanyile R, Munga Y, Ebenhan T, Zeevaart JR, Sathekge M. Kgatle M, et al. Among authors: ndlovu h. J Clin Med. 2023 Jan 9;12(2):529. doi: 10.3390/jcm12020529. J Clin Med. 2023. PMID: 36675457 Free PMC article.
225Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings.
Sathekge M, Bruchertseifer F, Vorster M, Lawal IO, Mokoala K, Reed J, Maseremule L, Ndlovu H, Hlongwa K, Maes A, Morgenstern A, Van de Wiele C. Sathekge M, et al. Among authors: ndlovu h. Eur J Nucl Med Mol Imaging. 2023 Jun;50(7):2210-2218. doi: 10.1007/s00259-023-06165-9. Epub 2023 Mar 3. Eur J Nucl Med Mol Imaging. 2023. PMID: 36864360 Free PMC article.
Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer.
Lawal IO, Morgenstern A, Vorster M, Knoesen O, Mahapane J, Hlongwa KN, Maserumule LC, Ndlovu H, Reed JD, Popoola GO, Mokoala KMG, Mdlophane A, Bruchertseifer F, Sathekge MM. Lawal IO, et al. Among authors: ndlovu h. Eur J Nucl Med Mol Imaging. 2022 Aug;49(10):3581-3592. doi: 10.1007/s00259-022-05778-w. Epub 2022 Apr 6. Eur J Nucl Med Mol Imaging. 2022. PMID: 35384462 Review.
18 results